HLA-DOA and neoplasm: While for allogeneic NKs, particularly human lymphocyte antigen (HLA)-unmatched donors are typically selected, a mismatch occurred between KIR and HLA that enhanced after expansion, and which conferred stronger anti-tumor potency in allogeneic eNKs.